Skip to Main Content

The $5 billion deal that Gilead CEO Daniel O’Day presented as his signature move shortly after his arrival at the company two years ago has gone up in flames.

Gilead announced Wednesday that it and partner Galapagos NV stopped the Phase 3 studies of a drug called zirataxestat, for idiopathic pulmonary fibrosis, because an independent data monitoring committee said the drug’s potential benefits were unlikely to outweigh its risks. That follows the failure of filgotinib, for rheumatoid arthritis, to reach the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.